Trial Profile
This Study is a Non-Randomized, Open-Label, Multi-Center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors GSK
- 03 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2008 Positive results reported at ESMO according to GlaxoSmithKline media release.
- 12 Sep 2008 Interim results will be reported at the 33rd Congress of the European Society for Medical Oncology (ESMO), according to a GlaxoSmithKline media release.